<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389177</url>
  </required_header>
  <id_info>
    <org_study_id>EMS-Pem</org_study_id>
    <nct_id>NCT04389177</nct_id>
  </id_info>
  <brief_title>Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC</brief_title>
  <official_title>Efficacy and Safety of Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe and evaluate the efficacy and safety of pembrolizumab
      plus paclitaxel, cisplatin followed by Da Vinci robot radical surgery for locally advanced
      esophageal squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Preoperative chemoradiotherapy with surgery is the standard treatment in NCCN guideline.
      But many patients refused or abandon radiotherapy because of the intolerable adverse effects.
      We designed a single-arm, open-label, phase II trial of pembrolizumab plus paclitaxel,
      cisplatin followed by Da Vinci robot radical surgery for locally advanced (stage III)
      esophageal squamous cell cancer. The purpose of this study is to observe and evaluate the
      efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major pathologic response</measure>
    <time_frame>3 months</time_frame>
    <description>Viable tumor comprised ≤ 10% of resected tumor specimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3 months</time_frame>
    <description>Partial response is defined as a decrease by 30% or more in sums of longest diameter of measurable target lesions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from the enrollment to disease relapse after complete resection or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>Time from the enrollment to death of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph node derating rate</measure>
    <time_frame>At time of surgery</time_frame>
    <description>Lymph node derating rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>At time of surgery</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <condition>Stage III</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab+ Paclitaxel+Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab 200mg, D1; Paclitaxel 135mg/m2, D2; Cisplatin 20mg/ m2，D2～D4; repeated every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab Injection [Keytruda]</intervention_name>
    <description>preoperative therapy with three cycles: Pembrolizumab 200mg D1; Paclitaxel 135mg/m2 D2; Cisplatin 20mg/m2 D2-D4; repeated every 3 weeks</description>
    <arm_group_label>Pembrolizumab+ Paclitaxel+Cisplatin</arm_group_label>
    <other_name>paclitaxel</other_name>
    <other_name>cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed esophageal squamous cell carcinoma;

          2. Potentially resectable cT3N1M0，cT1-3N2M0(stage III);

          3. PD-L1(+)，CPS≥10;

          4. ECOG: 0~1;

          5. Age 18-70 years old, both men and women.

        Exclusion Criteria:

          1. Prior therapy (operation, radiotherapy, immunotherapy, or chemotherapy) for esophageal
             cancer;

          2. Ineligibility or contraindication for esophagectomy;

          3. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
             immunosuppressive therapy within 7 days prior to the first dose of study drug;

          4. Has active autoimmune disease that has required systemic treatment in the past 2 years
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive
             drugs);

          5. Has severe hypersensitivity and adverse events (≥Grade 3) to nivolumab and/or any
             PD-1/PD-L1 inhibitors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaobin Shang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University Cancer Institute and Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaobin Shang, MD,PhD</last_name>
    <phone>18622221071</phone>
    <email>shangxiaobin@tmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaobin Shang, MD,PhD</last_name>
      <phone>18622221071</phone>
      <email>shangxiaobin@tmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaobin Shang, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

